FDA may allow more drugs to be sold without prescription.

FDA may establish a "behind-the-counter" system allowing more drugs that currently require a prescription to be sold without one, "The Wall Street Journal" reported Oct. 4.

In a notice published in the Federal Register, the agency announced a Nov. 14 hearing to explore "the public health benefit of drugs being available without a prescription but only after intervention by a pharmacist."

Such intervention could require a pharmacist to make sure a patient meets certain criteria to get a particular drug and to instruct the patient how to properly use it.

Currently, most drugs are sold either with a prescription or over the counter in retail stores and pharmacies. The agency has carved out a few exceptions, including limiting distribution of Barr Pharmaceuticals' "Plan B" emergency-contraceptive pill to pharmacies that agreed to keep it behind the counter and to require women to show photo identification to prove they are age 18 or older.

Some groups that have called for a behind-the-counter status for drugs have said it might allow certain drugs sold with a prescription to be safely sold without one.

In 2005, an FDA panel of outside medical experts turned down a bid by Merck and Johnson & Johnson to sell Mevacor, a cholesterol-lowering drug, without a prescription. Several panel members said FDA should consider establishing a behind-the-counter system that would allow consumers to purchase Mevacor from pharmacists much like the British are allowed to purchase Merck's Zocor, another cholesterol-lowering drug. Most panel members said that if such a system existed in the U.S., they would have voted to allow Mevacor to be sold without a prescription.

FDA noted that other countries with behind-the-counter status include Australia, Canada, New Zealand, Denmark, Germany, Italy, the Netherlands, Sweden and Switzerland.

Along with a Nov. 14 meeting to solicit public comments on the issue, FDA said it is also seeking written or electronic comments on the issue until Nov. 28.

The agency said it wants input on such issues as whether there should be a behind-the-counter status for certain drugs and whether the status should be a transitional way for prescription products to eventually move to over-the-counter status, where consumers can purchase products on store shelves. Other questions include the impact on patient safety and whether it would improve access to medications.

The agency said certain logistical questions would need to be addressed, including pharmacy storage and dispensing of the medications along with questions about whether and how pharmacists might be reimbursed.